Home / Insights / Patient Pool Trends by Therapeutic Area for Clinical Trial Conduct

insights-espresso-icon article

Patient Pool Trends by Therapeutic Area for Clinical Trial Conduct

Espresso-live Speakers
by Mathini Ilancheran
12 November 2014

Oncology & Immunomodulators category is found to be the most active therapeutic area with 7,326 projects in development which contributes to approximately 32% of all R&D projects in pipeline. On the other hand, Muscoskeletal, Dermatology and Anti-infectives have seen tremendous growth at a CAGR of 8.2 - 9.6% within the period 2008 to 2013. Global CROs with full service capabilities have higher number of patients enrolled under Cardiovascular and Oncology disease areas as they focus more on Phase II-IV trials rather than early phase trials. However, there exists specialist CROs within the markets, who focus on a particular therapeutic area and have access to specific patient population such as Bio-skin for Dermatology, Iris Pharma for Ophthalmology, etc. Based on the R&D project count as of 2013 and number of patients in the patient database of the CROs, a heat map is drawn showing which therapeutic area is seeing the highest demand from pharmaceutical companies and� therapeutic areas which have higher patient pools, followed by medium and low patient pools. What is the Current Market Scenario? Oncology & Immunomodulators category is found to be the most active therapeutic area with 7,326 projects in development which contributes to approximately 32% of all R&D projects in pipeline. Following Oncology is Infectious diseases, having a project count of 3530 i.e. 15% contribution among all R&D projects [1, 3].   Author: Mathini Ilancheran

SHARE
Linkedin Twitter Facebook
Leave a comment

Please enter a valid name

Post your comment

Please select captcha

Instagram

Get more stories like this

Subscirbe for more news,updates and insights from Beroe